Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.45 |
| ▸ | FEN1 | P39748 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770616 | 1.00 | MEN1 (0.47) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1642799 | 0.84 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5318849 | 0.83 | MAOB (0.51) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3539048 | 0.83 | CYP19A1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2ALOX5AP | |
| SCHEMBL2194408 | 0.83 | CYP19A1 (0.66) | ALDH1A1SMN1; SMN2CYP19A1LTA4H | |
| SCHEMBL26036511 | 0.80 | KDR (0.45) | ALOX5APFEN1KDR | |
| SCHEMBL1936332 | 0.80 | POLB (0.49) | ALDH1A1CYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL24414328 | 0.79 | MYC (0.46) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL15915600 | 0.79 | ALOX5AP (0.49) | MEN1KMT2APOLBALOX5APFEN1 | |
| SCHEMBL12439723 | 0.78 | MAOB (0.62) | CYP1A2CYP2C19L3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055021-B1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4025568-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-115298184-B | Heterocyclic RIP1 inhibiting compounds | 里格尔药品股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230143161-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143161-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2021046382-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046382-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143161-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | MEN1 2028/4885KMT2A 3657/4885ALDH1A1 4391/4885 |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | MEN1 2540/4885KMT2A 3696/4885ALDH1A1 4505/4885 |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | MEN1 351/4885KMT2A 3747/4885ALDH1A1 1677/4885 |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | MEN1 1165/4885KMT2A 2620/4885ALDH1A1 1926/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | MEN1 248/4885KMT2A 3740/4885ALDH1A1 1459/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | MEN1 2540/4885KMT2A 3696/4885ALDH1A1 4505/4885 |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | MEN1 2028/4885KMT2A 3657/4885ALDH1A1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.